Author(s): Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ
BACKGROUND: Patients with moderate to severe hidradenitis suppurativa (HS) failing adalimumab therapy, or those ineligible to receive it, remain a population with an unmet need.
METHODS: 20 patients not eligible for adalimumab were randomized to receive 12 weeks blind treatment with placebo or MABp1, a true human antibody targeting interleukin (IL)-1alpha. HS clinical response score at week 12 was the primary endpoint.
RESULTS: The primary endpoint was met in 10% and 60% of placebo- and MABp1-treated patients respectively (odds ratio 13.50, 95% confidence intervals 1.19-152.51). Clinical efficacy was maintained at 24 weeks in nil and 40%. Improvement in the visual analogue scale was reported by 20% and 85.7% of patients failing previous anti-TNF treatment. Ultrasound showed decreased neovascularization and lesion skin depth in the MABp1 group. MABp1 treatment was associated with decrease of circulating IL-8 and of stimulated production of IL-8 by whole blood. Whole blood production for human β-defensin (hBD)-2 was negatively associated with ultrasound changes in the placebo group but not in the MABp1 group.
CONCLUSIONS: MABp1 is a promising treatment for HS not eligible for adalimumab. Inhibition of neovascularization and modulation of the production of IL-8 and hBD-2 are suggested mechanisms of action.
Dermatology Journal and/or Publisher
Journal Name: The Journal of investigative dermatology
Journal Abbreviation: J. Invest. Dermatol.
Journal Date Published: 2017-11-13
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/29129600
Lasted Revision: 2017-11-13
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).